BAM66409 Ruxolitinib
INCB018424 (Ruxolitinib) is an orally bioavailable JAK inhibitor (IC50 values for JAK1, JAK2 and JAK3 are 3, 5 and 332 nM, respectively). Quantity Price 5 mg 99.00 10 mg 165.00 50 mg 470.00 100 mg 725.00 200 mg 1180.00            
structure C17H18N6
941678-49-5
98+%
MFCD12031592
BAM66410 Tasocitinib
Tasocitinib also known as CP690550 or Tofacitinib is an JAK kinase inhibitor. An IC50 estimated at 0.2 µM for PV patient progenitor cells. Quantity Price 10 mg 45.00 25 mg 110.00 50 mg 200.00 100 mg 360.00 200 mg 660.00 1 g 2270.00        
structure C16H20N6O
477600-75-2
98+%
MFCD11035919
BAM66411 LY2784544
LY2784544 is a small molecule selective mutant JAK2 kinase inhibitor with an IC50 of 68 nM. Quantity Price 5 mg 80.00 10 mg 160.00 50 mg 550.00 200 mg 1570.00                
structure C23H25ClFN7O
1229236-86-5
98+%
MFCD19443122
BAM66409 INCB018424
INCB018424 (Ruxolitinib) is an orally bioavailable JAK inhibitor (IC50 values for JAK1, JAK2 and JAK3 are 3, 5 and 332 nM, respectively). Quantity Price 5 mg 99.00 10 mg 165.00 50 mg 470.00 100 mg 725.00 200 mg 1180.00            
structure C17H18N6
941678-49-5
98+%
MFCD12031592
BAM66410 Tofacitinib
Tasocitinib also known as CP690550 or Tofacitinib is an JAK kinase inhibitor. An IC50 estimated at 0.2 µM for PV patient progenitor cells. Quantity Price 10 mg 45.00 25 mg 110.00 50 mg 200.00 100 mg 360.00 200 mg 660.00 1 g 2270.00        
structure C16H20N6O
477600-75-2
98+%
MFCD11035919
[1/2]